Evidence map›Paper›PMID 39820774›Full record

ReviewCurrent pain and headache reports2025

Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.

Isabella Henderson, Ronnie Elsaadany, Gabriel Chan, Vikram Bajaj, Diana Duarte, Sadie Goodman, Michael Grunstein, Nehal P Vadhan, Robert A Duarte

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isabella Henderson *Northwell Health Department of Neurology, New York, NY, USA. ihenderson1@northwell.edu.
Ronnie Elsaadany *Northwell Health Department of Neurology, New York, NY, USA.
Gabriel Chan *Northwell Health Department of Neurology, New York, NY, USA.
Vikram BajajNorthwell Health Department of Neurology, New York, NY, USA.
Diana DuarteNorthwell Health Department of Neurology, New York, NY, USA.
Sadie GoodmanNorthwell Health Department of Neurology, New York, NY, USA.
Michael GrunsteinNorthwell Health Department of Neurology, New York, NY, USA.
Nehal P VadhanNorthwell Health Department of Psychiatry, New York, NY, USA.
Robert A DuarteNorthwell Health Department of Neurology, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewExploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed. RECENT

findingsPsychedelics demonstrate promising outcomes as treatments for headache disorders. Recent findings indicated that some patients who underwent brief periods of treatment with psychedelics experienced a reduction in headache attack frequency, severity, or duration. When prescription medications are ineffective at treating headache disorders, or are habit-forming, patients often turn to alternative options. There is anecdotal evidence that psychedelic drugs like LSD and psilocybin can effectively treat and prevent pain in patients with headache disorders, such as migraine or cluster headache. It is vital that physicians treating patients who self-treat with psychedelics be well-informed about the mechanisms and their effects to best advise their patients and coordinate their care well. This is a review assessing the literature on the mechanisms, safety, and efficacy of psychedelic drugs as a headache management intervention. We believe there is evidence that may support further investigation into the clinical use of psychedelic medications to treat cluster headache and migraine, including the consideration of use in conjunction with other interventions like cognitive behavioral therapy or acceptance and commitment training.

Indexed as

HallucinogensHeadache DisordersHumansLysergic Acid DiethylamidePsilocybinTreatment OutcomeHallucinogensLysergic Acid DiethylamidePsilocybinCluster HeadacheHeadache DisorderLysergic Acid DiethylamideMigrainePsilocybinPsychedelics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.